TP53 and leukemia: If TP53 mutants indeed enhance KMT2A activity through KMT2A partners such as MEN1, TP53-mutant leukemia including AEL may benefit from the recent development of highly potent and selective small molecules blocking the functionally critical interaction of KMT2A and Menin.146